Ipilimumab

Generic Name: Ipilimumab

Brand Names: Yervoy

Drug Type: Biotech

Chemical Formula: -

CAS Number: 477202-00-9

Unique Ingredient Identifier: 6T8C155666

Background: Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

Ipilimumab was granted FDA approval on 25 March 2011.

Indication: Ipilimumab is indicated in the following cancerous conditions:

Melanoma

Renal Cell Carcinoma (RCC)

Colorectal Cancer

Hepatocellular Carcinoma

Non-Small Cell Lung Cancer (NSCLC)

Malignant Pleural Mesothelioma

Esophageal Cancer
...

Associated Conditions: Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)

Associated Therapies: First Line Chemotherapy

Clinical Trials

Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: SipT Treatment
Drug: Ipilimumab

First Posted Date: 2013-03-05

Last Posted Date: 2021-08-18

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 50

Registration Number: NCT01804465

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Phase 1

Completed

Conditions: Solid Tumours

Interventions: Drug: Dabrafenib
Drug: Ipilimumab
Drug: Trametinib

First Posted Date: 2013-01-14

Last Posted Date: 2017-11-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 38

Registration Number: NCT01767454

Locations: 🇺🇸
GSK Investigational Site, Houston, Texas, United States

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

Phase 1

Completed

Conditions: CANCER, NOS

Interventions: Drug: Lirilumab
Drug: Ipilimumab

First Posted Date: 2012-12-17

Last Posted Date: 2015-07-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 22

Registration Number: NCT01750580

Locations: 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸
University Of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Memorial Sloan Kettering Cancer Ctr, New York, New York, United States

and more 3 locations

Ipilimumab and Lenalidomide in Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: Ipilimumab
Drug: Lenalidomide

First Posted Date: 2012-12-17

Last Posted Date: 2019-02-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 101

Registration Number: NCT01750983

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Drug: Talimogene laherparepvec
Drug: Ipilimumab

First Posted Date: 2012-12-04

Last Posted Date: 2024-05-14

Lead Sponsor: Amgen

Target Recruit Count: 217

Registration Number: NCT01740297

Locations: 🇩🇪
Research Site, Tübingen, Germany

A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: CANCER,NOS

Interventions: Drug: Lirilumab
Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2012-10-26

Last Posted Date: 2023-02-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 337

Registration Number: NCT01714739

Locations: 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸
UPMC Eye and Ear Institute, Pittsburgh, Pennsylvania, United States
🇺🇸
Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States

and more 21 locations

Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Phase 2

Active, not recruiting

Conditions: Stage IIIA Cutaneous Melanoma AJCC v7
Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7
Recurrent Melanoma
Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions: Biological: Ipilimumab
Other: Laboratory Biomarker Analysis
Biological: Recombinant Interferon Alfa-2b

First Posted Date: 2012-10-17

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 88

Registration Number: NCT01708941

Locations: 🇺🇸
Cancer Center of Kansas - Chanute, Chanute, Kansas, United States
🇺🇸
Marietta Memorial Hospital, Marietta, Ohio, United States
🇺🇸
Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States

and more 274 locations